Global Coronary Artery Disease Therapeutics Market 2017-2021

This market research study identifies AstraZeneca, Gilead, Novartis, and Pfizer as the leading players in the global coronary artery disease therapeutics market. A comprehensive analysis of this market is also presented by drug class (beta-blockers, calcium channel blockers, nitrates, ACE inhibitors, and others) and by geography (the Americas, APAC, and EMEA). 

Overview of the global coronary artery disease therapeutics market

The incidence of chronic diseases such as diabetes, obesity, and high blood pressure is increasing across the globe. This creates a huge economic burden on the global healthcare system. Our research analysis on the global coronary artery disease therapeutics market has identified that the increase in the number of chronic diseases will be one of the major factors that will have a positive impact on this market’s growth during the next few years. A large number of patients are experiencing a low quality of life due to the uncontrolled blood sugar level. This can result in death. The lack of awareness and treatment facilities in Africa is resulting in an increased number of diabetic patients. According to the studies, countries such as China, India, and the US have the largest number of diabetic patients. This will further boost the demand for coronary artery disease therapeutics. Based on the coronary artery disease therapeutics industry analysis, this market will grow at a CAGR of more than 5% by 2021.

The fragmented nature of the market results in a division of profits among too many participants. This leaves the participants with minimal economic benefits. As a result, the coronary artery disease therapeutics market is witnessing a growth in the number of strategic alliances and acquisitions. In addition to acquisitions, the vendors are also focusing on entering into partnerships and are also forming joint ventures to develop new and better drugs.

Competitive landscape and key vendors

The coronary artery disease therapeutics market is highly competitive and is characterized by the presence of a large number of large, small, and medium-sized vendors. The vendors are increasingly competing against each other based on factors such as aggressive pricing, product efficacy, limited side effects, rich pipeline, and operational base. The rise in the number of mergers and acquisitions, product extensions, and the rising investments in R&D activities will strengthen the market’s competitive environment.

Key vendors in this market are 

• AstraZeneca
• Gilead
• Novartis
• Pfizer

Other prominent vendors in the market include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Mylan, and Teva Pharmaceutical Industries

Segmentation by drug class and analysis of the coronary artery disease therapeutics market

• Beta-blockers
• Calcium channel blockers
• Nitrates
• ACE inhibitors

Beta-blockers drugs reduce the blood pressure and heart rate by blocking the effect of stress hormones such as adrenaline. Acebutolol, atenolol, carvedilol, labetalol, metoprolol, penbutolol, pindolol, and propranolol are some of the common beta-blockers that are used for the treatment of cardiovascular diseases. The beta-blockers drug class is highly preferred over other drug classes because they enable the damaged heart to work more effectively. This, in turn, will stimulate the coronary artery disease treatment market growth in this segment.

Segmentation by geography and analysis of the coronary artery disease therapeutics market

• Americas
• APAC
• EMEA

Based on the coronary artery disease therapeutics market regional outlook, the consumption of drugs for cardiovascular disease (CAD) in the Americas is increasing due to the rising incidences of heart disease in the region. The region is heavily investing in the healthcare sector, which in turn, will drive the coronary artery disease therapeutics market’s growth in the region. The US is the major revenue generator in the region due to the presence of the pharmaceutical giants and the high prevalence rate of CAD.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global coronary artery disease therapeutics market?
• What are the key market trends impacting the growth of the global coronary artery disease therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global coronary artery disease therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global coronary artery disease therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global coronary artery disease therapeutics market?

Technavio also offers customization on reports based on specific client requirement.